HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TRANSTHERA-B

73.300

-2.500-3.30%

Volume:532.00K

Turnover:39.52M

Market Cap:29.10B

PE:-93.13

High:78.700

Open:75.800

Low:70.500

Close:75.800

52wk High:78.900

52wk Low:20.200

Shares:397.00M

HK Float Shares:301.67M

Volume Ratio:2.11

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.787

ROE:-65.31%

ROA:-35.56%

PB:45.70

PE(LYR):-93.13

PS:- -

Loading ...

Overview Company News Filings

HK Movers | Transthera-B, DualityBio-B Shares Surged About 16% After Being Added to the List of Securities for Southbound Trading

Tiger Newspress

TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect

TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing

TransThera Sciences Announces First Patient Dosed in Phase II Clinical Trial for Advanced Liver Cancer Treatment

Stock Track | TransThera Sciences Soars 8.53% Amid Broader Biotech Rally in Hong Kong

HK Movers | Biotech Stocks Surge With Cutia Therapeutics up 14%

Tiger Newspress

TRANSTHERA-B (02617) Selected for Inclusion in Hang Seng Index Series

TransThera Sciences Narrows Loss in H1

MT Newswires Live

BRIEF-TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 Million

Transthera Sciences (Nanjing) Inc - Hy Loss Attributable RMB122.9 Mln

THOMSON REUTERS

TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock

TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%

MT Newswires Live

BRIEF-Transthera Sciences (Nanjing) Inc Says Grant Of Tinengotinib (Tt-00420) Fast Track Designation

HK Movers | Biopharmaceutical Company TransThera Soars 80% on Debut

Tiger Newspress

Stock Track | TransThera Sciences Soars 63% on Hong Kong Debut Following Oversubscribed IPO

TransThera Sciences Raises HK$161 Million from IPO Ahead of Hong Kong Trading Debut

MT Newswires Live

TransThera Sciences Launches Up to HK$201 Million IPO in Hong Kong

MT Newswires Live

BRIEF-Transthera Sciences (Nanjing) Says Number Of Offer Shares Under Global Offering 15.3 Million H Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02617/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"TRANSTHERA-B","latestPrice":73.3,"timestamp":1757388905194,"preClose":75.8,"halted":0,"volume":532000,"delay":0,"floatShares":301666673,"shares":397000000,"eps":-0.7870528706948923,"marketStatus":"Trading","change":-2.5,"latestTime":"09-09 11:36:22","open":75.8,"high":78.7,"low":70.5,"amount":39524945,"amplitude":0.108179,"askPrice":73.85,"askSize":1000,"bidPrice":73.05,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.134776643067433,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1757390400000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":75.8,"openAndCloseTimeList":[[1757381400000,1757390400000],[1757394000000,1757404800000]],"volumeRatio":2.108339,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":301666673,"roa":"-35.56%","roe":"-65.31%","lyrEps":-0.787069,"volumeRatio":2.108339,"shares":397000000,"dividePrice":0,"high":78.7,"amplitude":0.108179,"preClose":75.8,"low":70.5,"week52Low":20.2,"pbRate":"45.70","week52High":78.9,"institutionHeld":0,"latestPrice":73.3,"committee":-0.333333,"eps":-0.787069158954788,"divideRate":0,"volume":532000,"delay":0,"ttmEps":-1.1348001275594846,"open":75.8,"prevYearClose":13.15,"prevWeekClose":63.1,"prevMonthClose":54.15,"prevQuarterClose":30.15,"fiveDayClose":63.2,"twentyDayClose":48.28,"sixtyDayClose":13.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2025-09-05","current":-57.867887,"percent":0.277778,"low":-72.789898,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"high":-17.403134,"avg":-50.543146,"sd":12.786891,"marketCap":25044240642},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642}],"updateTime":1757366325789},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1174923850","title":"HK Movers | Transthera-B, DualityBio-B Shares Surged About 16% After Being Added to the List of Securities for Southbound Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1174923850","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174923850?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:51","pubTimestamp":1757299883,"startTime":"0","endTime":"0","summary":"Transthera-B, DualityBio-B shares surged about 16% after being added to the list of securities for Southbound Trading.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","02617"],"gpt_icon":0},{"id":"1160465691","title":"TRANSTHERA-B Surges Nearly 11% in Early Trading to New Listing High as Company Joins Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1160465691","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160465691?lang=en_us&edition=fundamental","pubTime":"2025-09-08 10:20","pubTimestamp":1757298056,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) jumped over 10% in early trading, reaching an intraday high of HK$78, setting a new record since its listing. As of press time, the stock was up 10.54% to HK$69.75, with a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","07226","HSTECH","YANG","BK1161","02617","BK4614"],"gpt_icon":1},{"id":"1153459765","title":"TRANSTHERA-B (02617): Phase II Clinical Trial of Tinengotinib Combined with AKESO's Kantani® (Cadonilimab, PD-1/CTLA-4) / Ivonesca® (Ivonescimab, PD-1/VEGF) Completes First Patient Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=1153459765","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153459765?lang=en_us&edition=fundamental","pubTime":"2025-09-04 22:46","pubTimestamp":1756997181,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that the open-label, multi-center Phase II clinical studies of its core product Tinengotinib (TT-00420) in combination with AKESO Limited's Kantani® (Cadonilimab,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","LU0561508036.HKD","BK1574","LU0348827113.USD","LU2488822045.USD","LU0417516738.SGD","LU1794554557.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1720050803.USD","LU2778985437.USD","LU0348825331.USD","BK1161","PD","LU0634319403.HKD","LU0348783233.USD","LU0540923850.HKD","LU0417516902.SGD","LU2476274308.USD","LU0348767384.USD","LU0348735423.USD","LU0348766576.USD","LU1169589451.USD","IE00BPRC5H50.USD","02617","09926","BK4023","LU2476274720.SGD","LU0348784397.USD","LU1169590202.USD"],"gpt_icon":1},{"id":"2564038133","title":"TransThera Sciences Announces First Patient Dosed in Phase II Clinical Trial for Advanced Liver Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564038133","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564038133?lang=en_us&edition=fundamental","pubTime":"2025-09-04 22:34","pubTimestamp":1756996463,"startTime":"0","endTime":"0","summary":"TransThera Sciences  Inc. has announced the initiation of a Phase II clinical trial involving their Core Product, Tinengotinib , in combination with Akeso, Inc.'s cadonilimab  and ivonescimab  for the treatment of advanced hepatocellular carcinoma . The trial is an open-label, multicenter study conducted in China, aimed at evaluating the safety and efficacy of these combination therapies in patients who have not previously received systemic anticancer therapy for HCC or have failed prior standard treatments. The announcement noted that this clinical study marks the first dosing of a patient, while results from the trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transthera Sciences  Inc. published the o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL6Wxz7r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2488822045.USD","LU0540923850.HKD","LU0561508036.HKD","LU0417516902.SGD","LU2476274720.SGD","LU0348766576.USD","LU0417516738.SGD","LU0348767384.USD","LU0634319403.HKD","BK1574","LU0348735423.USD","LU0348827113.USD","LU0348825331.USD","IE00B543WZ88.USD","LU2778985437.USD","BK1161","LU1720050803.USD","LU0417516571.SGD","LU2476274308.USD","LU0348783233.USD","LU0348784397.USD","02617","IE00B5MMRT66.SGD","LU1794554557.SGD"],"gpt_icon":1},{"id":"1136230353","title":"Stock Track | TransThera Sciences Soars 8.53% Amid Broader Biotech Rally in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1136230353","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136230353?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:40","pubTimestamp":1756435232,"startTime":"0","endTime":"0","summary":"TransThera Sciences (02617.HK) saw its stock soar by 8.53% during intraday trading on Friday, as part of a broader surge in Hong Kong's biotech sector. The significant uptick in TransThera's share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5f33b3b5eefd72d982b2d94c09297262","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"gpt_icon":0},{"id":"1183779957","title":"HK Movers | Biotech Stocks Surge With Cutia Therapeutics up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183779957","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183779957?lang=en_us&edition=fundamental","pubTime":"2025-08-29 10:38","pubTimestamp":1756435121,"startTime":"0","endTime":"0","summary":"Biotech stocks surged in Hong Kong on Friday. Cutia Therapeutics rose 14%; Antengene rose 13%; HBM Holdings and TransThera Sciences rose 9%; RemeGen rose 8%; CARsgen Therapeutics rose 7%; WuXi...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"5f33b3b5eefd72d982b2d94c09297262","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02171","02269","06996","02617","02142","02487"],"gpt_icon":0},{"id":"1139681939","title":"TRANSTHERA-B (02617) Selected for Inclusion in Hang Seng Index Series","url":"https://stock-news.laohu8.com/highlight/detail?id=1139681939","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139681939?lang=en_us&edition=fundamental","pubTime":"2025-08-25 22:38","pubTimestamp":1756132713,"startTime":"0","endTime":"0","summary":"TRANSTHERA-B (02617) announced that following the quarterly review results published by Hang Seng Indexes Company Limited on August 22, 2025, the company has been selected for inclusion in various...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","HHImain","HSI","MHImain","02833","MCHmain","513600","159271","HSImain","BK1161"],"gpt_icon":0},{"id":"2562247307","title":"TransThera Sciences Narrows Loss in H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2562247307","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562247307?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:33","pubTimestamp":1756128812,"startTime":"0","endTime":"0","summary":"TransThera Sciences  narrowed its attributable loss to 122.9 million yuan in the first half of 2025 from 160.4 million yuan a year prior, a Monday Hong Kong bourse filing said.Loss per share for the clinical-stage biopharmaceutical firm was 0.32 yuan, down from 0.42 yuan in the year-ago period.The firm did not record revenue in the period.Other income and gains, on the other hand, fell 65.1% to 3.6 million yuan in the six months from 10.4 million yuan a year prior, mainly due to a lower interest income from bank deposits and wealth management products, as well as a decline in government grants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2562244773","title":"BRIEF-TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2562244773","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562244773?lang=en_us&edition=fundamental","pubTime":"2025-08-25 21:02","pubTimestamp":1756126931,"startTime":"0","endTime":"0","summary":"BRIEF-TransThera Sciences (Nanjing) Inc Posts HY Loss Attributable RMB122.9 MillionAug 25 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:HY LOSS ATTRIBUTABLE RMB122.9 MILLIONFurther company coverage: 2617.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2562413622","title":"Transthera Sciences (Nanjing) Inc - Hy Loss Attributable RMB122.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2562413622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562413622?lang=en_us&edition=fundamental","pubTime":"2025-08-25 20:19","pubTimestamp":1756124370,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nFWN3UH0GZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"1103128195","title":"TRANSTHERA-B (02617) Included in Hang Seng Composite Index, Expected to Become Hong Kong Stock Connect Eligible Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1103128195","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103128195?lang=en_us&edition=fundamental","pubTime":"2025-08-22 20:48","pubTimestamp":1755866914,"startTime":"0","endTime":"0","summary":"On August 22nd, Hang Seng Indexes Company announced the quarterly review results of the Hang Seng Index Series as of June 30, 2025. TRANSTHERA-B (02617) was included in the Hang Seng Composite Index,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YANG","07226","HSCI","BK4614","02617","BK1161","HSCEI","HSTECH"],"gpt_icon":1},{"id":"2545778427","title":"TransThera Gets US FDA Fast Track Designation for Prostate Cancer Drug; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545778427","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545778427?lang=en_us&edition=fundamental","pubTime":"2025-06-24 10:01","pubTimestamp":1750730465,"startTime":"0","endTime":"0","summary":"TransThera Sciences  said the US Food and Drug Administration has granted fast-track designation for tinengotinib to treat metastatic castration-resistant prostate cancer , according to a Tuesday Hong Kong bourse filing.In a phase 1/2 study, the drug showed a 46% objective response rate and 85% disease control rate among 13 mCRPC patients with measurable disease, the filing said.TransThera said the latest designation reflects consistent clinical execution and supports further development of the drug for advanced prostate cancer.Shares of the clinical-stage biopharmaceutical firm rose about 3% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B5TLWC47.USD","02617","FAST","BK4567","BK4104","BK4585","IE00BYQQ9H92.USD","BK4588","IE00BFXG0V08.USD"],"gpt_icon":1},{"id":"2545271254","title":"BRIEF-Transthera Sciences (Nanjing) Inc Says Grant Of Tinengotinib (Tt-00420) Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2545271254","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545271254?lang=en_us&edition=fundamental","pubTime":"2025-06-24 09:59","pubTimestamp":1750730399,"startTime":"0","endTime":"0","summary":"BRIEF-Transthera Sciences  Inc Says Grant Of Tinengotinib  Fast Track DesignationJune 24  - TransThera Sciences  Inc 2617.HK:GRANT OF TINENGOTINIB  FAST TRACK DESIGNATION FOR TREATMENT OF MCRPC BY US FDAFurther company coverage: 2617.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nFWN3SQ0VB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1112813016","title":"HK Movers | Biopharmaceutical Company TransThera Soars 80% on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1112813016","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112813016?lang=en_us&edition=fundamental","pubTime":"2025-06-23 11:13","pubTimestamp":1750648381,"startTime":"0","endTime":"0","summary":"On debut today, Biopharmaceutical company TransThera soared 80% in Hong Kong.The company has yet to bring any products to market, but it has six drug candidates in clinical trials and one in pre-clini","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"1b427ba95419e94342a8c5dcdde518cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":1},{"id":"1139156968","title":"Stock Track | TransThera Sciences Soars 63% on Hong Kong Debut Following Oversubscribed IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1139156968","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139156968?lang=en_us&edition=fundamental","pubTime":"2025-06-23 09:34","pubTimestamp":1750642447,"startTime":"0","endTime":"0","summary":"TransThera Sciences  made a spectacular debut on the Hong Kong Stock Exchange, with its shares soaring 63.12% in early trading. The impressive rally comes on the heels of the company's highly successful initial public offering , which raised HK$161.3 million in net proceeds.The clinical-stage biopharmaceutical firm's IPO garnered significant investor interest, particularly in its Hong Kong component. The local offering was an astounding 3,419.87 times oversubscribed, prompting the company to dou","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"1b427ba95419e94342a8c5dcdde518cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Stock Track | TransThera Sciences Soars 63% on Hong Kong Debut Following Oversubscribed IPO","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02617"],"gpt_icon":1},{"id":"2545459574","title":"TransThera Sciences Raises HK$161 Million from IPO Ahead of Hong Kong Trading Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2545459574","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545459574?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:28","pubTimestamp":1750634906,"startTime":"0","endTime":"0","summary":"TransThera Sciences (Nanjing) (HKG:2617) raised HK$161.3 million in net proceeds from its initial public offering in Hong Kong, according to a Friday after-market filing with the Hong Kong bourse.The ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"df918633255108433bafea673bf4d3c4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02617"],"gpt_icon":1},{"id":"2543579573","title":"TransThera Sciences Launches Up to HK$201 Million IPO in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2543579573","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543579573?lang=en_us&edition=fundamental","pubTime":"2025-06-13 11:06","pubTimestamp":1749783992,"startTime":"0","endTime":"0","summary":"TransThera Sciences  launched its initial public offering in Hong Kong that seeks to raise up to HK$200.9 million, according to a Friday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm is offering as much as 15,281,000 shares at an indicative price of HK$13.15 each.TransThera secured five cornerstone investors, including Jiangbei Pharmaceutical, Akeso , Sinohsc Honest, Pharmablock Horizon, and Kelingan, which committed to subscribe for a combined HK$130.0 million worth of IPO shares, representing around 64.1% of the offering.The issuer expects to determine its offer price and disclose the allocations on June 20. It will then start trading on the Hong Kong bourse on June 23, according to a prospectus filing.Proceeds from the deal will primarily fund a multiregional Phase III trial of its core product Tinengotinib, with remaining funds allocated to general working capital and corporate purposes.CLSA, Huatai Financial, BOCOM International, BOCI Asia, CMB International, S","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B543WZ88.USD","02617","IE00B5MMRT66.SGD","LU0417516571.SGD","LU1720050803.USD","LU2488822045.USD","09926","IE00BPRC5H50.USD","BK1161","LU0348784397.USD","LU1794554557.SGD","BK1574","LU0348783233.USD"],"gpt_icon":0},{"id":"2543524819","title":"BRIEF-Transthera Sciences (Nanjing) Says Number Of Offer Shares Under Global Offering 15.3 Million H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2543524819","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543524819?lang=en_us&edition=fundamental","pubTime":"2025-06-13 09:24","pubTimestamp":1749777891,"startTime":"0","endTime":"0","summary":"BRIEF-Transthera Sciences  Says Number Of Offer Shares Under Global Offering 15.3 Million H SharesJune 13  - Transthera Sciences  2617.HK:NUMBER OF OFFER SHARES UNDER GLOBAL OFFERING 15.3 MILLION H SHARESOFFER PRICE UNDER GLOBAL OFFERING HK$13.15 PER H SHARENUMBER OF HONG KONG OFFER SHARES UNDER GLOBAL OFFERING 1.5 MILLION H SHARESFurther company coverage: [ ] ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nFWN3SF0MQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}